Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.48
+1.14 (10.05%)
Mar 9, 2026, 3:06 PM EDT - Market open
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
427.50M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 129.42M |
| Autolus Therapeutics | 51.13M |
| Assembly Biosciences | 37.19M |
| Entrada Therapeutics | 25.42M |
| Lineage Cell Therapeutics | 14.56M |
| Upstream Bio | 2.80M |
| 4D Molecular Therapeutics | 120.00K |
| vTv Therapeutics | 17.00K |
BNTC News
- 5 weeks ago - Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade - Seeking Alpha
- 2 months ago - Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response - GlobeNewsWire
- 4 months ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 4 months ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 4 months ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 4 months ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire
- 5 months ago - Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update - GlobeNewsWire